These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 30659989)

  • 1. Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.
    Zheng MM; Li YS; Jiang BY; Tu HY; Tang WF; Yang JJ; Zhang XC; Ye JY; Yan HH; Su J; Zhou Q; Zhong WZ; Yang XN; Guo WB; Chuai S; Zhang Z; Chen HJ; Wang Z; Liu C; Wu YL
    J Thorac Oncol; 2019 May; 14(5):924-932. PubMed ID: 30659989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
    Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
    Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].
    Li H; Xie Y; Lin Y; Yu T; Yin Z
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):646-654. PubMed ID: 32838487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
    Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
    Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
    BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
    Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
    Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis.
    Nie N; Zhou H; Zhang K; Liu L; Luo N; Wang R; Li X; Zhu M; Hu C; Wang Y; Liu Z; Li L; He Y
    Thorac Cancer; 2022 Sep; 13(18):2574-2583. PubMed ID: 35896160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis.
    Chiang CL; Lee CC; Huang HC; Wu CH; Yeh YC; Shen CI; Luo YH; Shiao TH; Chang HJ; Huang YT; Chen YM; Chou TY; Chiu CH
    Target Oncol; 2021 Mar; 16(2):207-214. PubMed ID: 33566300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
    Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
    J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells.
    Jiang BY; Li YS; Guo WB; Zhang XC; Chen ZH; Su J; Zhong WZ; Yang XN; Yang JJ; Shao Y; Huang B; Liu YH; Zhou Q; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Wu SY; Gao CY; Zhang X; Wu YL
    Clin Cancer Res; 2017 Sep; 23(18):5480-5488. PubMed ID: 28606923
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.
    Shi L; Guo L; Tao H; Meng Q; Tong L; Tang J; Li K; Zhang S; Liu Z
    Thorac Cancer; 2023 Jul; 14(19):1883-1893. PubMed ID: 37287428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
    Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
    Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
    Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
    J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.
    Miao Q; Zheng X; Li L; Zheng X; Zhang L; Jiang K; Wu S; Wang H; Wu B; Xu Y; Zhong Q; Zou Z; Zhang Q; Yang S; Li Y; Lin G
    J Neurooncol; 2023 Dec; 165(3):517-525. PubMed ID: 38104049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
    Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
    Kawamura T; Murakami H; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Endo M; Takahashi T
    Invest New Drugs; 2019 Feb; 37(1):184-187. PubMed ID: 29971546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.